Contact us
English
Menu
Contact us

The Feldan Shuttle: Optimized for Functional, Safe, and Broad Delivery

Shuttle image

Overcomes endosomal entrapment — a major obstacle to effective intracellular drug delivery 

 

ASO image

Enables local delivery of functional antisense oligonucleotides (ASOs) and other therapeutic cargos 

Lung image

Achieves rapid delivery into a wide range of cells and tissues, including the skin and lungs — two organs known for their challenging natural barriers that limit traditional delivery methods

Safety image

With a robust safety profile demonstrated in preclinical studies, the Feldan Shuttle led to the advancement of our lead candidate, FLD-103, into clinical trials

Feldan Shuttle Endosomal Escape

Unlocking the Full Potential of Antisense Oligonucleotides with the Feldan Shuttle

Antisense oligonucleotides (ASOs) are a class of RNA therapeutics that selectively silence disease-driving genes.​ Despite their precision and therapeutic potential, ASOs face a major challenge: they cannot cross cell membranes on their own, limiting their effectiveness. The Feldan Shuttle addresses this barrier by efficiently delivering ASOs into cells, enabling them to reach their intracellular targets and achieve their intended therapeutic effect.​
The Feldan Shuttle unlocks the therapeutic promise of ASOs and expands their application in novel therapies.

The Power of Local Administration

Local administration offers key advantages that improve therapeutic outcomes:

Increases
Treatment Efficacy
Limits
Systemic Exposure
Improves
Safety Profile
Beyond the local administration of ASO-based therapies, the Feldan Shuttle platform has demonstrated potential for various therapeutic applications where intracellular delivery is key.
Shuttle Figure

Proof-of-Concept Publications  

The Feldan Shuttle has been the subject of publications in renowned journals, demonstrating its ability to efficiently deliver therapeutic cargos into cells, where they can engage their intracellular targets. This peer-reviewed work — some developed in collaboration with academic partners — reflects our scientific engagement and our platform’s broad potential. 

Nature_Communications_Logo

Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo.

Katarina Kulhankova, Soumba Traore, Xue Cheng, Hadrien Benk-Fortin, Stéphanie Hallée, Mario Harvey, Joannie Roberge, Frédéric Couture, Sajeev Kohli, Thomas J. Gross, David K. Meyerholz, Garrett R. Rettig, Bernice Thommandru, Gavin Kurgan, Christine Wohlford-Lenane, Dennis J. Hartigan-O’Connor, Bradley P. Yates, Gregory A. Newby, David R. Liu, Alice F. Tarantal, David Guay & Paul B. McCray Jr., Nat Commun 14, 8051 (2023). doi: 10.1038/s41467-023-43904-w. PMID: 38052872

Nature_Communications_Logo

Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia.

Krishnamurthy S, Wohlford-Lenane C, Kandimalla S, Sartre G, Meyerholz DK, Théberge V, Hallée S, Duperré AM, Del'Guidice T, Lepetit-Stoffaes JP, Barbeau X, Guay D, McCray PB Jr.,  Nat Commun. 2019 Oct 28;10(1):4906. doi: 10.1038/s41467-019-12922-y.  PMID: 31659165

 

Plos One

Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells.

Del'Guidice T, Lepetit-Stoffaes JP, Bordeleau LJ, Roberge J, Théberge V, Lauvaux C, Barbeau X, Trottier J, Dave V, Roy DC, Gaillet B, Garnier A, Guay D. PLoS One. 2018 Apr 4;13(4):e0195558. doi: 10.1371/journal.pone.0195558. eCollection 2018. PMID:29617431